RxDoctor Payments Data

Joseph Seipel, MD

Neurology · New Albany, INNPI 1043213408

Payments from drug & device makers

$3,540in general payments, 2019–2025

Across 193 payments — averaging $18.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Livanova USA, Inc.$2K
  • Pfizer$756
  • AbbVie$528
  • Boston Scientific$165
  • Biogen$115
  • Sunovion Pharmaceuticals Inc.$93
  • plus $319 from 15 others

What the payments were for

  • Travel & lodging$79522%
  • Food & beverage$2,74578%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,540 in reported general payments places this provider in the 50th percentile of 308 neurology providers in Indiana.

See all neurology providers in Indiana

Medicare billing

Part B allowed, 2024
$122,471
Medicare patients
905
Services billed
1,244

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate102$158,950
QuliptaAtogepant60$74,763
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5016$63,892
Lacosamide289$42,584
VimpatLacosamide13$31,102
BriviactBrivaracetam27$25,037
ValtocoDiazepam31$22,740
LamictalLamotrigine11$20,744
Oxcarbazepine133$18,178
DilantinPhenytoin Sodium Extended54$14,602
Tegretol XrCarbamazepine12$13,406
Levetiracetam431$13,314
RytaryCarbidopa/Levodopa12$13,220
Carbamazepine ErCarbamazepine64$12,421
Emgality PenGalcanezumab-Gnlm16$11,910

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt, Dilantin$756$173,552156 claims
AbbVieQulipta$528$74,76360 claims
UCB, Inc.Vimpat, Briviact$26$56,14040 claims
Neurelis, Inc.Valtoco$19$22,74031 claims
Amneal Pharmaceuticals LLCRytary$12$13,22012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 308 neurology providers in Indiana.

Other neurology in New Albany

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →